PMID- 38084637
OWN - NLM
STAT- MEDLINE
DCOM- 20240305
LR  - 20240305
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 39
IP  - 3
DP  - 2024 Mar
TI  - Pretreatment eosinophil count predicts response to atezolizumab plus bevacizumab 
      therapy in patients with hepatocellular carcinoma.
PG  - 576-586
LID - 10.1111/jgh.16441 [doi]
AB  - AIM: Pretreatment peripheral blood markers have value in predicting the treatment 
      outcome of various cancers. In particular, the eosinophil count has recently 
      gained attention. However, no study has reported the influence of the 
      pretreatment eosinophil count on the outcomes of atezolizumab plus bevacizumab 
      (ATZ/BEV), which is the recommended first-line systemic therapy for unresectable 
      hepatocellular carcinoma (u-HCC). METHODS: We enrolled 114 patients with u-HCC 
      treated with ATZ/BEV (n = 48) or lenvatinib (n = 66). The patients receiving 
      ATZ/BEV or lenvatinib were divided into two groups by calculating the cutoff 
      value of the pretreatment eosinophil count. The groups were compared regarding 
      the clinicopathological characteristics, outcomes, and incidence of adverse 
      events (AEs). RESULTS: Twenty-three of 48 patients (47.9%) who received ATZ/BEV 
      therapy were categorized as the ATZ/BEV-eosinophil-high group, which had better 
      responses than the ATZ/BEV-eosinophil-low group (P = 0.0090). Kaplan-Meier curves 
      revealed a trend toward significantly better progression-free survival (PFS) in 
      the ATZ/BEV-eosinophil-high group than the ATZ/BEV-eosinophil-low group (the 
      median PFS: 4.7 months in the ATZ/BEV-eosinophil-low group vs 12.6 months in the 
      ATZ/BEV-eosinophil-high group; P = 0.0064). Multivariate analysis showed that a 
      low eosinophil count was an independent risk factor for worse PFS after ATZ/BEV 
      therapy (P = 0.0424, hazard ratio: 2.24, 95% confidence interval: 1.02-4.89). AEs 
      (>/= grade 3) were significantly more likely to occur in the 
      ATZ/BEV-eosinophil-high group (P = 0.0285). The outcomes did not significantly 
      differ between the LEN-eosinophil-high group and the LEN-eosinophil-low group. 
      CONCLUSION: A high pretreatment eosinophil count predicted a better response to 
      ATZ/BEV therapy for u-HCC and was associated with the incidence of AEs (>/= grade 
      3).
CI  - (c) 2023 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Toshida, Katsuya
AU  - Toshida K
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Itoh, Shinji
AU  - Itoh S
AUID- ORCID: 0000-0003-0382-2520
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Yoshiya, Shohei
AU  - Yoshiya S
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Nagao, Yoshihiro
AU  - Nagao Y
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Tomino, Takahiro
AU  - Tomino T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Izumi, Takuma
AU  - Izumi T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Iseda, Norifumi
AU  - Iseda N
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Toshima, Takeo
AU  - Toshima T
AUID- ORCID: 0000-0003-4019-8288
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Ninomiya, Mizuki
AU  - Ninomiya M
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
FAU - Yoshizumi, Tomoharu
AU  - Yoshizumi T
AD  - Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, 812-8582, Japan.
LA  - eng
GR  - JP19K-09198/Japan Society for the Promotion of Science/
GR  - JP23K-08133/Japan Society for the Promotion of Science/
PT  - Journal Article
DEP - 20231212
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 52CMI0WC3Y (atezolizumab)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - Bevacizumab/adverse effects
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Eosinophils
MH  - *Liver Neoplasms/drug therapy
MH  - *Phenylurea Compounds
MH  - *Quinolines
MH  - *Antibodies, Monoclonal, Humanized
OTO - NOTNLM
OT  - Atezolizumab plus bevacizumab
OT  - Eosinophil count
OT  - Hepatocellular carcinoma
OT  - Lenvatinib
EDAT- 2023/12/12 06:42
MHDA- 2024/03/05 06:45
CRDT- 2023/12/12 05:31
PHST- 2023/11/11 00:00 [revised]
PHST- 2023/07/10 00:00 [received]
PHST- 2023/11/19 00:00 [accepted]
PHST- 2024/03/05 06:45 [medline]
PHST- 2023/12/12 06:42 [pubmed]
PHST- 2023/12/12 05:31 [entrez]
AID - 10.1111/jgh.16441 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2024 Mar;39(3):576-586. doi: 10.1111/jgh.16441. Epub 
      2023 Dec 12.